Skip to content

PLT to Present New Sleep Ingredient Study at American Academy of Sleep Medicine Conference

PLT Health Solutions, Inc. announced that it will be presenting clinical study results for its Serezin™ Restorative Sleep + Pain Relief ingredient at the American Academy of Sleep Medicine Conference being held June 7-11 in Seattle, WA USA. Dawna Salter-Farfan, PhD, RD, PLT’s Senior Clinical Research Manager, will be conducting a  poster session Wednesday, 6/11/2025, at 10:00 AM during the Clinical Sleep Science and Practice section. The session will cover results of a recent clinical trial on Serezin and will present data specifically on results with women. An abstract entitled  An Herbal Supplement Improves Restorative Sleep and Sleep Quality, Elevates Mood, and Increases Total Sleep Time,“  was published in the May edition of the journal SLEEP.

GOÄ Amendment: Threats Against Delegates of the Doctors' Assembly in Leipzig

The amendment to the German Medical Fee Schedule (GOÄ) recently passed at the 129th Doctors' Assembly in Leipzig has caused considerable concern in laboratory medicine. In an exclusive interview with MedLabPortal, Priv.-Doz. Dr. med. Matthias Orth, Chief Physician of the Institute for Laboratory Medicine at Marienhospital Stuttgart, expressed criticism of the reform's impact on his field. Orth, a specialist in laboratory medicine, medical hygiene, and hemostasiology, warned of a deterioration in patient care and rising treatment costs. The adoption of the GOÄ amendment was not surprising, according to Orth, as there was massive pressure on the delegates beforehand to accept the reform. General practitioners, who hope to benefit from the new regulation, as well as employed and retired doctors who are not directly affected, formed the majority. The aim of the reform is to curb treatment costs in the private health insurance sector. However, the planned devaluation of technical disciplines such as laboratory medicine below cost price will...

Diverse Function of B Cells in Tumorigenesis

  • News

B cells play a dual role in tumorigenesis: they act as both allies and adversaries within the tumor microenvironment (TME). Their anti-tumor functions include recognizing tumor-associated antigens, producing antibodies, activating cytotoxic immune responses, and forming tertiary lymphoid structures (TLS), which enhance immune cell coordination. Tumor-infiltrating B cells (TIL-Bs) within TLS contribute to improved patient survival and better responses to immunotherapies by promoting antibody class switching, somatic hypermutation, and cytokine secretion, which in turn recruit and activate T cells, natural killer (NK) cells, and dendritic cells (DCs). Antibodies produced by B cells mediate complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and antibody-dependent cellular cytotoxicity (ADCC), directly eliminating tumor cells. Additionally, B cells present antigens to T cells and secrete cytokines such as IFN-γ and CXCL13, thereby enhancing anti-tumor immunity. However, regulatory B cells (Bregs) and other subsets suppress immune responses by secreting IL-10, TGF-β… 

Abnormal uterine bleeding and insulin resistance are on the rise

Insulin resistance is becoming increasingly common due to a combination of lifestyle factors, genetics, and medical conditions. Many of these risk factors also play a role in abnormal uterine bleeding. A new study aims to demonstrate the link between these two factors to better predict abnormal uterine bleeding. The study’s findings were published online today in  Menopause , the journal of The Menopause Society. Abnormal uterine bleeding has become more common, affecting approximately 30% of women of reproductive age. It costs the healthcare system more than $34 billion annually, not to mention the additional economic burden of increased work absenteeism and overall reduced quality of life. Currently, much of the research in this area focuses on the diagnosis and treatment of abnormal uterine bleeding rather than prevention, with a focus on reducing cardiovascular risk factors as a treatment method. At the same time, cases of insulin resistance are increasing,… 

The Merz Government's Debt Disaster: Special Funds as a Risk to Innovation and Intergenerational Equity

With the introduction of a special fund of 500 billion euros, Chancellor Friedrich Merz has made one of the most radical about-faces in German fiscal policy. Merz had categorically ruled out any loosening of the debt brake during the election campaign. Just days after the election, the new grand coalition of CDU/CSU and SPD agreed on a credit-financed mega-package that breaks previous standards and discards the principles of the "black zero" and fiscal discipline[5][7][3]. The special fund is intended to flow into the modernization of infrastructure, defense, digitalization, and research and innovation over the next ten years. Specifically, billions will be provided for the backlog of repairs in schools, universities, hospitals, roads, and the railway system. At the same time, high-tech sectors such as quantum computing, artificial intelligence, and space travel are to be specifically promoted to strengthen Germany's innovative capacity[2][8][1]. The SPD also wants to drive forward green tech, hydrogen, and sustainable production. But the money attracts desires: from Deutsche Bahn, which is demanding almost 150 billion euros ...

USA: $104 Trillion in Debt Crushes Healthcare

  • News

The US national debt reached a new high in May 2025 at around $36.9 trillion and continues to rise dynamically[1][2][13]. Per capita, this corresponds to a debt of about $108,000, with total debt – including private debt – even exceeding $104 trillion[1][2]. The debt-to-GDP ratio, the ratio of national debt to gross domestic product (GDP), is about 124 percent at the beginning of 2025 and is projected to continue rising[1][7][14]. The main drivers of this development, besides high defense spending and interest payments, are primarily the constantly increasing costs in the healthcare sector[14][16]. Consequences for the Healthcare Sector The US healthcare sector is the most expensive in the world: the US spends more than twice the OECD average per capita on health[3][4]. A significant portion of the federal budget flows into programs like Medicare and Medicaid, whose expenses are driven by an aging population and rising prices for medications and medical ...

Opium Poppy: Germany Becomes Opium Land

  • News

In Germany, 1066 hectares of opium poppies were cultivated in 2024. This is an increase of around 50% compared to the previous year. In 2023, the cultivation area was still 701 hectares. This brings the figure back almost to the level of 2021, when the total cultivation area reached its previous peak of 1077 hectares. This is the result of a current analysis by the Federal Opium Agency, which is part of the Federal Institute for Drugs and Medical Devices (BfArM). Bavaria leads among the federal states with a cultivation area of 285.1 hectares. Saxony follows in second place with 256.5 hectares, and Lower Saxony in third place with 105.2 hectares. The strongest increase in cultivation area was seen in Thuringia. There, the area more than tenfold increased from 5.1 hectares to 59.1 hectares. Further significant increases were observed in Brandenburg (from 7.2 hectares to 49.2 hectares) and Saxony-Anhalt (from 41.4 hectares to 98.7 hectares). It also increased… 

Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC

Johnson & Johnson today announced first results from the Phase 3, randomized, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) genetic alterations including BRCA. The results show a clinically meaningful and statistically significant improvement in both radiographic progression-free survival (rPFS) and time to symptomatic progression (TSP), with an early trend toward improved overall survival (OS)—highlighting the potential of the combination in this patient population to delay both cancer progression and the worsening of symptoms.1 This marks the first Phase 3 data to show clinical improvement with a PARP-based combination in mCSPC. The findings are being presented as a late-breaking oral presentation (Abstract #LBA5006) at the 2025 American Society of Clinical Oncology Annual Meeting. The data have also been selected for… 

Researchers find early trigger for prostate cancer aggressiveness

  • News

Researchers at the University of Michigan’s Rogel Cancer Center have discovered a gene that plays a key role in the transformation of prostate cancer cells into a more aggressive, treatment-resistant form. The gene can be indirectly targeted with an existing class of drugs, suggesting a potential treatment strategy for patients with aggressive prostate cancer subtypes. “Patients whose prostate tumors lose their dependence on the androgen receptor fare poorly. Our findings suggest a therapeutic approach for patients whose tumors have undergone this change,” said senior study author Dr. Joshi J. Alumkal, the Wicha Family Professor of Oncology at the University of Michigan Rogel Cancer Center. The work builds on previous studies that showed prostate cancer cells undergo a process called lineage plasticity, where they become resistant to the androgen receptor, a key target molecule in prostate cancer. This transition away from androgen receptor dependence is a continuum, with cancer cells taking on other identities… 

Synthetic compound shows promising effect against multidrug resistance

This week in Microbiology Spectrum, researchers describe a newly synthesized compound called infuzide that shows efficacy against multidrug-resistant strains of S. aureus and Enterococcus in lab and mouse tests. Furthermore, the results suggest infuzide kills bacteria in a different way than other antimicrobials, which could help keep resistance at bay. Infuzide is the result of more than a decade of interdisciplinary research seeking ways to develop compounds that act against pathogens in a similar way to known pharmaceutical compounds. These include hydrazones, inorganic synthesized compounds that have shown antibacterial activity, including against resistant strains, in previous studies. The researchers synthesized 17 new compounds containing hydrazones, and among these, infuzide showed activity against gram-positive S. aureus and Enterococcus. “We started the project as a collaboration, looking for ways to synthesize compounds and link them to compounds that are biological…